-
I was using PK-Sim for my PBPK project but I constantly encountered an issue: When I imported the observed concentration data to do a visual evaluation of my model, the value of the observed data chan…
-
Dear OSP-Community,
on behalf of the PBPK Tutorial Team at Saarland University we are happy to announce the first part of our OSP-Online tutorial series “Getting started with PK-Sim”. The series wa…
-
Applied Concepts in PBPK Modeling: How to Extend an Open Systems Pharmacology Model to the Special Population of Pregnant Women.
https://github.com/Open-Systems-Pharmacology/OSP-based-publications-…
-
Hi, I am learning PBPK. I was wondering which database (Array, RT-PCR or EST) one should use to add an expression of the protein. Is there any preference?
-
Does anyone know which ontogeny function for AAG is implemented within PK-Sim version 8.0? Is it the same as that listed in the PK-Sim® Ontogeny Database Version 7.3:
Mayer et al., A novel approach t…
-
I am developing a model of drug that is CYP3A4 substrate and its interaction with other drug on PK-Sim which only inhibits Intestinal CYP3A4, not hepatic CYP3A4.. how to control or inhibit just Intest…
HTQ05 updated
4 years ago
-
Note: accidently created this issue first before creating the math issue. The first comment below are relevant to the issue on the math repo.
#### Summary:
Expose the function described in math#11…
-
Hello All,
Iam trying to build PBPK model in rats for a NCE administered by IV Infusion for 1hour. I have physicochemical parameters, invitro data and invivo data.
My questions are
1. In the ind…
-
Dear all,
We have been working on models for DDI prediction, building a small network of interacting CYP1A2 perpetrator and victim drugs. Two whole-body PBPK models of fluvoxamine and theophylline …
-
I tried running simulations using PK-Sim 7.4 for metronidazole following 500mg IV as well as oral dosing. IV simulations were very close to the literature reported observed data whereas for oral route…